The Experts below are selected from a list of 1284 Experts worldwide ranked by ideXlab platform
Oscar Len - One of the best experts on this subject based on the ideXlab platform.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus isolates cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 h after nebulization without significant plasma concentrations. Nebulized micafungin may be a safe and effective option for the treatment of fungal Tracheobronchitis.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 hours after nebulization without significant plasma concentrations. Nebulized micafungin could be a safe and effective option for the treatment of fungal Tracheobronchitis.
Ibai Losarcos - One of the best experts on this subject based on the ideXlab platform.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus isolates cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 h after nebulization without significant plasma concentrations. Nebulized micafungin may be a safe and effective option for the treatment of fungal Tracheobronchitis.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 hours after nebulization without significant plasma concentrations. Nebulized micafungin could be a safe and effective option for the treatment of fungal Tracheobronchitis.
Donald E Craven - One of the best experts on this subject based on the ideXlab platform.
-
antibiotic therapy for ventilator associated Tracheobronchitis a standard of care to reduce pneumonia morbidity and costs
Current Opinion in Pulmonary Medicine, 2015Co-Authors: Donald E Craven, Jana Hudcova, Jawad RashidAbstract:Purpose of reviewThe present review draws our attention to ventilator-associated Tracheobronchitis (VAT) as a distinct clinical entity that has been associated with progression to ventilator-associated pneumonia (VAP) and worse patient outcomes. In contrast to VAP, which has been extensively investi
-
ventilator associated Tracheobronchitis pre emptive appropriate antibiotic therapy recommended
Critical Care, 2014Co-Authors: Donald E Craven, Jana Hudcova, Yuxiu LeiAbstract:Nseir and colleagues presented data from a large multicenter study of patients with ventilator-associated Tracheobronchitis (VAT), demonstrating that appropriate antibiotic therapy for VAT was an independent predictor for reducing transition to pneumonia (ventilator-associated pneumonia, or VAP). These data added to the growing evidence supporting the use of appropriate antibiotic therapy for VAT as a standard of care to prevent VAP and improve patient outcomes.
-
antibiotic treatment of ventilator associated Tracheobronchitis to treat or not to treat
Current Opinion in Critical Care, 2014Co-Authors: Donald E Craven, Jana Hudcova, Kathleen A Craven, Caitlin Scopa, Yuxiu LeiAbstract:Purpose of reviewTo evaluate the data on antimicrobial therapy for ventilator-associated Tracheobronchitis (VAT) to prevent ventilator-associated pneumonia (VAP), and its impact on patient outcomes.Recent findingsMechanically ventilated patients are at increased risk for tracheal colonization with b
-
incidence and outcomes of ventilator associated Tracheobronchitis and pneumonia
The American Journal of Medicine, 2013Co-Authors: Donald E Craven, Yuxiu Lei, Robin Ruthazer, Akmal Sarwar, Jana HudcovaAbstract:Abstract Background Prolonged intubation with mechanical ventilation carries a risk for ventilator-associated respiratory infections manifest as Tracheobronchitis or pneumonia. This study analyzed natural history, incidence, and outcomes of patients developing ventilator-associated Tracheobronchitis and pneumonia. Methods We studied 188 mixed intensive care unit (ICU) patients intubated ≥48 hours for the development of Tracheobronchitis defined as quantitative endotracheal aspirate ≥10 5 cfu/mL plus at least 2 clinical criteria (fever, leukocytosis, or purulent sputum). Pneumonia was defined as microbiologic criteria for Tracheobronchitis and a new and persistent infiltrate on chest radiograph. Results Airways of 41 (22%) patients became heavily colonized with a bacterial pathogen(s) at a concentration of ≥10 5 cfu/mL. Tracheobronchitis developed in 21 (11%) study patients, of which 6 (29%) later progressed to pneumonia. Including these 6 patients, 28 (15%) study patients developed pneumonia. Multidrug-resistant pathogens were isolated in 39% of pneumonia patients. Patients with Tracheobronchitis and pneumonia had significantly more ventilator days and longer stays in the ICU ( P ≤.02). Conclusions Approximately one third of Tracheobronchitis patients later developed pneumonia. Patients with Tracheobronchitis or pneumonia experienced significantly more ventilator days and longer ICU stays, but had no difference in mortality. Better patient outcomes and reduced health care costs may be achieved by earlier treatment of ventilator-associated respiratory infections, manifest as Tracheobronchitis or pneumonia.
-
diagnosis of ventilator associated pneumonia controversies and working toward a gold standard
Current Opinion in Infectious Diseases, 2013Co-Authors: Philip Grgurich, Jana Hudcova, Akmal Sarwar, Donald E CravenAbstract:Purpose of reviewThe aim is to discuss the clinical, microbiologic, and radiological criteria used in the diagnosis of ventilator-associated pneumonia (VAP), distinguish between ventilator-associated Tracheobronchitis (VAT) and VAP, and reconcile the proposed Centers for Disease Control surveillance
Saad Nseir - One of the best experts on this subject based on the ideXlab platform.
-
how can we distinguish ventilator associated Tracheobronchitis from pneumonia
Clinics in Chest Medicine, 2018Co-Authors: Sean Keane, Saad Nseir, Maria Sole Vallecoccia, Ignacio MartinloechesAbstract:Ventilator-associated Tracheobronchitis (VAT) might represent an intermediate process between lower respiratory tract colonization and ventilator-associated pneumonia (VAP), or even a less severe spectrum of VAP. There is an urgent need for new concepts in the arena of ventilator-associated lower respiratory tract infections. Ideally, the gold standard of care is based on prevention rather than treatment of respiratory infection. However, despite numerous and sometimes imaginative efforts to validate the benefit of these measures, most clinicians now accept that currently available measures have failed to eradicate VAP. Stopping the progression from VAT to VAP could improve patient outcomes.
-
should we treat ventilator associated Tracheobronchitis with antibiotics
Seminars in Respiratory and Critical Care Medicine, 2017Co-Authors: Ignacio Martinloeches, John D Coakley, Saad NseirAbstract:Patients admitted to intensive care units (ICUs) often require lung organ support. The use of mechanical ventilation, while lifesaving can be associated with subsequent complications. The most common complication in patients under mechanical ventilation is the development of ventilator-associated lower respiratory tract infections (VA-LRTIs). Before the development of VA-LRTI, there is a continuum process that ranges from airway colonization to ventilator-associated pneumonia (VAP). There is an intermediate process called ventilator-associated Tracheobronchitis (VAT). Contemporary treatment of VA-LRTI emphasizes the importance of prompt broad-spectrum antimicrobial therapy. Previous studies reported prolonged duration of mechanical ventilation and ICU stay in patients with VAT. This negative impact on outcome is related to increased inflammation of the lower respiratory tract, sputum production, and higher rates of VAP. Extubation failure and difficult weaning have been reported to be associated with increased sputum volume in mechanically ventilated patients. Antibiotic treatment for VAT patients is still a matter for debate. Observational studies suggested a beneficial effect of antimicrobial treatment in VAT patients, including a reduced duration of mechanical ventilation and lower rates of subsequent VAP. Previous studies demonstrated beneficial effects of systemic and aerosolized antibiotics in preventing VAP in critically ill patients. However, antibiotic treatment is a recognized risk factor for the emergence of multidrug-resistant bacteria. Infections related to these bacteria are associated with increased morbidity, mortality, and cost. Therefore, a large well-designed study is warranted to determine whether patients with VAT should receive antimicrobials. Furthermore, a short course of antimicrobials could be sufficient in these patients.
-
ventilator associated Tracheobronchitis where are we now
Revista Brasileira De Terapia Intensiva, 2014Co-Authors: Saad Nseir, Ignacio MartinloechesAbstract:Histological studies revealed a continuum between these two infections. Several definitions are available for VAT. However, all of these definitions have some limitations. The most accepted and frequently used definition include the following criteria: fever >38o C with no other cause, purulent tracheal secretions, positive tracheal aspirate (≥10
-
From ventilator-associated Tracheobronchitis to ventilator-associated pneumonia
Réanimation, 2013Co-Authors: Ignacio Martin-loeches, Saad Nseir, Jordi Vallés, Antonio ArtigasAbstract:Ventilator-associated complications (VACs) are those complications that develop during the period of intubation. The most frequent VAC is infection. Ventilator-associated Tracheobronchitis (VAT) is one of the ventilator-associated complications occurring in the critically ill patient. This infection represents an intermediate process between lower respiratory tract colonization and ventilator-associated pneumonia. Increased duration of mechanical ventilation has been reported in patients with VAT because of increased sputum production and airway inflammation. Two studies have shown a beneficial effect of antimicrobial treatment in patients with VAT. The optimal duration of antimicrobial treatment in patients with VAT should be further investigated because short courses of antimicrobials might be sufficient. Aerosolized antibiotics also need to be compared to systemic antibiotics in these patients.
-
effect of ventilator associated Tracheobronchitis on outcome in patients without chronic respiratory failure a case control study
Critical Care, 2005Co-Authors: Saad Nseir, Christophe Di Pompeo, Stéphane Soubrier, Hélène Lenci, Pierre Delour, T Onimus, Fabienne Saulnier, Daniel Mathieu, Alain DurocherAbstract:Introduction Our objective was to determine the effect of ventilator-associated Tracheobronchitis (VAT) on outcome in patients without chronic respiratory failure.
Santiago Grau - One of the best experts on this subject based on the ideXlab platform.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus isolates cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 h after nebulization without significant plasma concentrations. Nebulized micafungin may be a safe and effective option for the treatment of fungal Tracheobronchitis.
-
nebulized micafungin treatment for scopulariopsis microascus Tracheobronchitis in lung transplant recipients
Antimicrobial Agents and Chemotherapy, 2021Co-Authors: Ibai Losarcos, Cristina Berastegui, Santiago Grau, María Deu, Judith Sacanell, Nuria Campillo, Carles Bravo, Maria Teresa Martingomez, David Campanyherrero, Oscar LenAbstract:Scopulariopsis/Microascus cause infections with high mortality in lung transplant recipients. Treatment is challenging due to antimicrobial resistance. We describe two cases of Scopulariopsis/Microascus Tracheobronchitis in lung transplant recipients successfully treated with nebulized micafungin. This antifungal was well tolerated and achieved high concentrations in epithelial lining fluid up to 14 hours after nebulization without significant plasma concentrations. Nebulized micafungin could be a safe and effective option for the treatment of fungal Tracheobronchitis.
